Fundraising Fox

Alector

NASDAQ: ALECUnicorn · $1.9B

San Francisco, US · Founded 2013 · Delaware LLC · 131 employees on LinkedIn · 6 known investors

Find your way into Alector

85 people in our graph share verified history with the Alector team — schools, employers, funds. One of them is your warm intro.

Mohan S. Iyerunlockedknows Arnon Rosenthal PhD · together at Genentech Inc. (overlapped)
×10knows the team · via Genentech Inc.
knows the team · via Alector

Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration. The company focuses on patients with neurodegenerative conditions and applies genetics, neuroscience, and immunology to advance new treatments.

AI & Machine LearningBiotechHealthtechLongevityMedical Devices

Founders & leadership

Alector was founded in 2013 by Arnon Rosenthal, Tillman Gerngross, and Arnon Rosenthal PhD.

ARArnon Rosenthal
Arnon RosenthalinPh.D.Arnon Rosenthal holds a Ph.D. from Hebrew University of Jerusalem and spent over a decade at Genentech, where he advanced to executive scientist and initiated the research program underlying Erivedge. He co-founded Rinat Neuroscience in 2001, which was acquired by Pfizer in 2006 with several programs in pain, migraine, and neurodegenerative indications, and later co-founded Annexon Biopharmaceuticals before becoming co-founder and CEO of Alector, which develops immune-based therapies for neurodegenerative diseases.
TG
Tillman GerngrossCo-founder
ARArnon Rosenthal PhD
Arnon Rosenthal PhDinCo-Founder and CEOArnon Rosenthal holds a PhD from the Hebrew University of Jerusalem and previously worked as a scientist and executive staff scientist at Genentech before co-founding Rinat Neuroscience (acquired by Pfizer) and Annexon, where he served as CEO and board chair. He is co-founder and CEO of Alector, a biotechnology company developing microglia immune checkpoint therapies for Alzheimer's and other forms of dementia, and has served as a visiting professor at UCSF's Department of Anatomy.

Board

CG
Carl GordonBoard director
TMTerry McGuire
Terry McGuireinBoard directorFounding Partner at Polaris Partners

Investors · 6

Foresite CapitalWest Hollywood
Mission Bay CapitalSan Francisco
Mission BiocapitalSan Francisco · $500K
MRL Ventures FundCambridge · $25M
SV Health InvestorsBoston · $1M – $20M
Polaris PartnersreportedBoston · $500K – $5Mvia Terry McGuire · board

Reported raises · per SEC filings

Form D private placements

$32.3M disclosed across 1 round · 2015

▶$32.3MraisedSep 2015 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Carl GordonDirector
  • Tillman GerngrossDirector
  • Arnon RosenthalExecutive Officer, Director
  • Terry McGuireDirector
Offering amount
$32.3M
Amount sold
$32.3M
First sale
Sep 2015
Incorporated
Limited Liability Company, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$1.9Bvaluation at IPOJan 2020 · $25.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

3 people who came through Alector went on to found or lead other companies.

Errik AndersonCo-FounderFounded Cantai Therapeutics +4Sabah OneyVice President, Business Development and OperationsFounded Vilya +1Josh ResnickBoard DirectorFounded Mariana Oncology +1

Competitors · 3

by search overlap
Seeking Alpha30 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood29 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Eli Lilly28 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

Companies competing with Alector for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Alector (NASDAQ:ALEC) Shares Up 7.9% – What’s Next? - Daily Politicaldailypolitical.com · Jul 2026Weekly News Roundup | 13 July 2026 | Life Science Daily Newslifesciencedaily.news · Jul 2026Alector raises $133 million in Series E round for neurology drug development - MedCity Newsmedcitynews.com · Jul 2018

Frequently asked questions

What does Alector do?
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration. The company focuses on patients with neurodegenerative conditions and applies genetics, neuroscience, and immunology to advance new treatments.
Who founded Alector?
Alector was founded by Arnon Rosenthal, Tillman Gerngross, Arnon Rosenthal PhD in 2013.
Who are Alector's investors?
Alector's investors include Foresite Capital, Mission Bay Capital, Mission Biocapital, MRL Ventures Fund, SV Health Investors, Polaris Partners.
How much funding has Alector raised?
Alector has disclosed $32.3M raised across 1 round.
Where is Alector headquartered?
Alector is headquartered in San Francisco, US.